Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $148,000.

  • Apellis Pharmaceuticals' Capital Expenditures was N/A to $148,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $225,000, marking a year-over-year change of. This contributed to the annual value of $403,000 for FY2024, which is 47.87% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Capital Expenditures stood at $148,000, which was up 202.04% from $49,000 recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Capital Expenditures peaked at $851,000 during Q4 2022, and registered a low of $8,000 during Q1 2025.
  • Over the past 3 years, Apellis Pharmaceuticals' median Capital Expenditures value was $92,500 (recorded in 2023), while the average stood at $138,100.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 97.33% in 2021, then surged by 4,378.95% in 2022.
  • Apellis Pharmaceuticals' Capital Expenditures (Quarterly) stood at $19,000 in 2021, then spiked by 4,378.95% to $851,000 in 2022, then plummeted by 88.84% to $95,000 in 2023, then plummeted by 78.95% to $20,000 in 2024, then tumbled by 45.56% to $148,000 in 2025.
  • Its last three reported values are $148,000 in Q3 2025, $49,000 for Q2 2025, and $8,000 during Q1 2025.